3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
8
Sarcoma
6
Breast Neoplasms
4
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Merkel Cell
2
Skin Neoplasms
1
Sarcoma, Kaposi
1
Pleural Effusion, Malignant
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Inflammatory Breast Neoplasms
1
Hemangiosarcoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Ductal, Breast
1
Carcinoma, Ductal
1
Carcinoma, Basal Cell
1
Breast Carcinoma In Situ
1
Interventions
Cyclophosphamide
41
Peripheral Blood Stem Cell Transplantation
40
fludarabine phosphate
36
Whole-Body Irradiation
27
Mycophenolic Acid
27
Tacrolimus
23
Busulfan
23
Cyclosporine
22
Antilymphocyte Serum
20
Etoposide
17
Methotrexate
16
Filgrastim
16
Melphalan
14
romidepsin
13
Radiotherapy
13
Flow Cytometry
12
Methylprednisolone
10
Brentuximab Vedotin
10
Therapeutics
9
Psychiatric Rehabilitation
9
Lenalidomide
8
pembrolizumab
7
fludarabine
7
Sirolimus
7
Rituximab
7
Bortezomib
7
Bexarotene
7
mogamulizumab
6
Polymerase Chain Reaction
6
Gemcitabine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, T-Cell, Cutaneous
×
talimogene laherparepvec
×
Clear all
NCT03458117
2022-03-18
20139157 T-VEC
University of Zurich
Phase 1
Completed
26 enrolled